Transferrin Receptor Protein-1 (TFRC) HEK293 Cell Line
Transferrin Receptor Protein-1 (TFRC) HEK293 Cell Line are engineered HEK293 cells to express full length human Transferrin Receptor Protein-1 (TFRC and TFR1, also known as human CD71 protein, GenBank accession #NM_001128148), a cell surface receptor involved in iron homeostasis. Deregulated iron homeostasis links to multiple disease including Parkinson’s Disease, Amyotrophic Lateral Sclerosis (ALS), Huntington’s Disease, Multiple Sclerosis (MS), and tumorigenesis. This cell line was validated by flow cytometry for surface expression of TFRC and can be used in multiple applications, such transferrin endocytosis studies and binding assays.
Purchase of this cell line is for research purposes only; commercial use requires a separate license. View the full terms and conditions.
Materials Required for Cell Culture
| Name | Ordering Information |
| Thaw Medium 1 | BPS Bioscience #60187 |
| Growth Medium 1C | BPS Bioscience #79532 |
The cell line has been screened using the MycoAlert™ Mycoplasma Detection kit (Lonza, #LT07-218) to confirm the absence of Mycoplasma species.
Transferrin Receptor Protein-1 (TFRC) is a cell surface receptor that binds ferric-iron-loaded transferrin in the bloodstream at high affinity to facilitate iron uptake into cells. TFRC is therefore an integral component of the body’s iron supply chain and general homeostasis. Intracellular iron levels, hypoxia and CRE signaling regulate TFRC transcription. In addition, TFRC is upregulated in correlation with tumor-progressive stages of multiple forms of cancer. At the cellular level iron surplus results in oxygen radical formation and cellular dysfunction, while iron deficiency can cause rapid cell death. Deregulated iron levels are therefore correlated with multiple disease states including Parkinson’s Disease, Amyotrophic Lateral Sclerosis (ALS), Huntington’s Disease, Multiple Sclerosis (MS), and tumorigenesis.
Equally important are potential therapeutic uses of TFRC. As TFRC is upregulated on the surface of tumor cells, it has been targeted to inhibit adult T-cell leukemia/lymphoma. Additionally, TFRC has found important utility in treatments of neurological diseases. Drug discovery in the central nervous system (CNS) space has historically been challenged by limited access of therapeutics across the blood brain barrier (BBB). As TFRC is highly expressed on the surface of brain capillary endothelial cells within the BBB, drug delivery strategies are being developed to leverage transcytosis of TFRC-bound entities from the bloodstream to the CNS (i.e. receptor mediated transport, or RMT). Current approaches include PEGylated liposomes coated with the TFRC ligand transferrin, as well as anti-TFRC antibodies linked to nanoparticles (immunoliposomes) carrying a therapeutic payload.
Powered by Bioz
San Diego, CA 92121
858-202-1401
Products are for Research Use Only
COMPANY
Copyright © 2024
BPS Bioscience, Inc.
All rights reserved.
Diagrams on this website are created with BioRender.com.